Sera Prognostics, Inc. (SERA)
USD 3.34
(2.77%)
USD 3.34
(2.77%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 25.28 Million USD | 45.42% |
| 2022 | 17.38 Million USD | 105.39% |
| 2021 | 8.46 Million USD | -93.97% |
| 2020 | 140.36 Million USD | 8.07% |
| 2019 | 129.88 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 25.13 Million USD | -0.58% |
| 2024 Q2 | 25.1 Million USD | -0.11% |
| 2023 Q4 | 25.28 Million USD | 72.63% |
| 2023 Q2 | 15.54 Million USD | 0.93% |
| 2023 FY | 25.28 Million USD | 45.42% |
| 2023 Q1 | 15.4 Million USD | -11.42% |
| 2023 Q3 | 14.64 Million USD | -5.77% |
| 2022 Q2 | 8.15 Million USD | 6.38% |
| 2022 FY | 17.38 Million USD | 105.39% |
| 2022 Q1 | 7.66 Million USD | -9.49% |
| 2022 Q3 | 9.4 Million USD | 15.35% |
| 2022 Q4 | 17.38 Million USD | 84.92% |
| 2021 Q2 | 230.86 Million USD | 19.54% |
| 2021 Q3 | 3.65 Million USD | -98.42% |
| 2021 Q4 | 8.46 Million USD | 131.85% |
| 2021 FY | 8.46 Million USD | -93.97% |
| 2021 Q1 | 193.13 Million USD | 37.59% |
| 2020 FY | 140.36 Million USD | 8.07% |
| 2020 Q4 | 140.36 Million USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2019 FY | 129.88 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aspira Women's Health Inc. | 8.62 Million USD | -193.068% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -651.063% |
| Intelligent Bio Solutions Inc. | 5.59 Million USD | -351.831% |
| Standard BioTools Inc. | 159.86 Million USD | 84.185% |
| Inotiv, Inc. | 588.04 Million USD | 95.7% |
| Prenetics Global Limited | 44.01 Million USD | 42.556% |
| Neuronetics, Inc. | 81.64 Million USD | 69.031% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -16.646% |
| Castle Biosciences, Inc. | 86.54 Million USD | 70.785% |
| Psychemedics Corporation | 6.59 Million USD | -283.192% |
| RadNet, Inc. | 2.07 Billion USD | 98.781% |
| Exact Sciences Corporation | 3.32 Billion USD | 99.24% |
| IDEXX Laboratories, Inc. | 1.77 Billion USD | 98.576% |
| iSpecimen Inc. | 6.07 Million USD | -315.972% |
| OpGen, Inc. | 13.44 Million USD | -88.064% |
| Exagen Inc. | 34.25 Million USD | 26.181% |
| Bionano Genomics, Inc. | 118.24 Million USD | 78.618% |
| CareDx, Inc | 223.28 Million USD | 88.677% |
| Check-Cap Ltd. | 1.33 Million USD | -1800.977% |
| Twist Bioscience Corporation | 152.97 Million USD | 83.472% |
| Guardant Health, Inc. | 1.62 Billion USD | 98.447% |
| Biodesix, Inc. | 94.51 Million USD | 73.25% |
| BioNexus Gene Lab Corp. | 1.74 Million USD | -1351.427% |
| Precipio, Inc. | 3.67 Million USD | -588.535% |
| Natera, Inc. | 691.79 Million USD | 96.345% |
| Fulgent Genetics, Inc. | 139.82 Million USD | 81.918% |
| 23andMe Holding Co. | 206.64 Million USD | 87.765% |
| OPKO Health, Inc. | 622.47 Million USD | 95.938% |
| Personalis, Inc. | 95.65 Million USD | 73.569% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | 37.148% |
| Applied DNA Sciences, Inc. | 8.77 Million USD | -187.989% |
| T2 Biosystems, Inc. | 62.83 Million USD | 59.762% |
| Neogen Corporation | 1.44 Billion USD | 98.244% |
| Myriad Genetics, Inc. | 312.9 Million USD | 91.92% |
| ICON Public Limited Company | 7.74 Billion USD | 99.674% |
| NeoGenomics, Inc. | 739.69 Million USD | 96.582% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -16.646% |
| MDxHealth SA | 121.92 Million USD | 79.263% |
| Prenetics Global Limited | 44.01 Million USD | 42.556% |
| Illumina, Inc. | 4.36 Billion USD | 99.421% |
| DarioHealth Corp. | 38.24 Million USD | 33.892% |
| ENDRA Life Sciences Inc. | 1.09 Million USD | -2208.619% |
| Medpace Holdings, Inc. | 1.09 Billion USD | 97.697% |
| Mainz Biomed B.V. | 12.15 Million USD | -107.923% |
| Trinity Biotech plc | 83.38 Million USD | 69.679% |
| Sotera Health Company | 2.68 Billion USD | 99.059% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -651.063% |